Private Market View

Pharmakina

Bukavu, Congo · Founded 1961 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include African Union Development Agency-NEPAD, Talanton.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 2 names
  • ·Watchlist + deal alerts for Pharmakina
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Pharmakina are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Pharmakina

Provider of a pharmaceutical company intended for the plantation of cinchona. The company transforms its own quinine salts into finished pharmaceutical products, offering them as Active Pharmaceutical Ingredients (API) for export and as Finished Pharmaceutical Products (FPP) for the Democratic Republic of Congo and regional markets, enabling consumers with healthcare and life-saving treatments.

Sector
Healthcare
HQ
Bukavu, Congo
Founded
1961
Ownership
Privately Held (backing)
PA Mark — not yet priced

Pharmakina doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Pharmakina shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Pharmakina in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.